Form 4: Neurocrine Biosciences Insider Sells Shares Under 10b5-1 Plan

Neurocrine Biosciences Chief Legal Officer Darin Lippoldt reported transactions involving the sale of company stock, executed under a pre-established Rule 10b5-1 trading plan.

Summary

• Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc., reported several transactions on June 26 and June 29, 2026.
• These transactions involved the acquisition and disposition of common stock, executed under a Rule 10b5-1 trading plan adopted on June 9, 2025.
• Specifically, 200 shares were acquired at $81.49 and subsequently disposed of at a weighted average price of $169.565 on June 26.
• On June 29, 8,110 shares were acquired at $81.49 and disposed of at a weighted average price of $170.025, and an additional 1,690 shares were acquired at $81.49 and disposed of at a weighted average price of $170.8144.
• These dispositions were part of a broker-executed plan, with sales occurring at various prices within specified ranges.
• The reporting person's beneficial ownership of common stock remains significant after these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution under a pre-defined 10b5-1 plan and the continued significant beneficial ownership mitigate immediate concern.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-impactful sales.
• The reporting person, Darin Lippoldt, continues to hold a substantial number of Neurocrine Biosciences shares after the reported sales.
• The acquisition of shares at a lower price ($81.49) before disposition at higher prices suggests a strategy aligned with potential stock appreciation.

Negatives

• Significant sales of company stock by a key executive can sometimes be perceived negatively by the market, regardless of the plan's nature.
• The weighted average sale prices, while high, represent a divestment of equity by an insider.

Risks

• The filing does not explicitly detail risks associated with these specific transactions, but insider selling can sometimes signal a lack of confidence or a need for liquidity, which could be perceived as a risk by investors.
• The Rule 10b5-1 plan itself could be subject to scrutiny if not properly structured or executed, though the filing indicates adherence to its conditions.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future financial performance or strategic direction. It solely reports past transactions.

Management Comments

• The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2025.
• Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
• Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.56 to $169.57.
• Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $169.57 to $170.56.
• Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $170.58 to $170.91.
• The option was granted February 5, 2018 and vested in 48 equal monthly installments beginning March 5, 2018.

Industry Context

StockSavvy.ai notes that insider transactions, particularly under Rule 10b5-1 plans, are common in the biopharmaceutical sector as executives manage personal portfolios while adhering to trading regulations. The reported sales at prices significantly above the acquisition price reflect the potential for substantial stock appreciation in this industry, often driven by clinical trial progress or regulatory approvals.

Corporate Governance

Stakeholder Impact

• Shareholders: May interpret insider selling, even under a plan, with caution, though the pre-planned nature and continued ownership may temper concerns. The weighted average sale prices indicate a profitable divestment for the insider.
• Employees: The transactions do not directly impact employee compensation or benefits but may influence employee sentiment regarding stock value.
• Management: Reinforces the established procedures for insider stock transactions and corporate governance related to trading plans.

Next Steps

• Continue to monitor future Form 4 filings for any further insider transactions.
• Observe Neurocrine Biosciences' stock performance and corporate developments for broader investment insights.

Key Dates

Keywords

Form 4, Insider Trading, Rule 10b5-1, Neurocrine Biosciences, NBIX, Stock Sale, Beneficial Ownership, Darin Lippoldt, Chief Legal Officer, SEC Filing